ARRB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3238503	0.59	6/20
SCHEMBL3239924	0.59	6/20
SCHEMBL3243590	0.59	6/20
SCHEMBL3230874	0.46	3/20
SCHEMBL3240361	0.45	3/20
SCHEMBL5407338	0.44	3/20
SCHEMBL4663454	0.41	3/20
SCHEMBL3379026	0.40	3/20
SCHEMBL5403311	0.57	2/20
SCHEMBL2969390	0.53	2/20
SCHEMBL5403621	0.51	2/20
SCHEMBL5509157	0.50	2/20
SCHEMBL5673865	0.49	2/20
SCHEMBL5409451	0.48	2/20
Hydrochloric Acid (SCHEMBL5677140)	0.48	2/20
SCHEMBL4663505	0.47	2/20
SCHEMBL4698332	0.45	2/20
SCHEMBL6998218	0.44	2/20
SCHEMBL4663496	0.43	2/20
SCHEMBL3992921	0.41	2/20

Clinical trials — most relevant to ARRB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery	PHASE4	NOT_YET_RECRUITING
Oliceridine in Patients With Acute Burn Injuries	PHASE4	COMPLETED
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)	PHASE4	COMPLETED
Reversal of Acute β-Blocker Induced Bronchoconstriction	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation	PHASE3	COMPLETED
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer	PHASE3	COMPLETED
Best African American Response to Asthma Drugs	PHASE3	COMPLETED
Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder	PHASE2	COMPLETED
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer	PHASE2	NOT_YET_RECRUITING
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma	PHASE2	UNKNOWN
Genetic Influences of Albuterol Response In Children With Bronchiolitis	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Influence of Nebivolol on Postmenopausal Women	nan	UNKNOWN
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia	nan	COMPLETED
Can Caudal Dexmedetomidine Provide Effective Analgesia?	nan	NOT_YET_RECRUITING
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
The Mechanism of Endogenous Nociceptin/Orphanin FQ(N/OFQ) and β1-adrenoceptor Autoantibody in Promoting Ischemic Arrhythmia in Rats	nan	NOT_YET_RECRUITING
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ARRB1 binder may also engage these)

Protein	Name	Similarity
P17870	—	1.000	P17870 →
P29066	—	1.000	P29066 →
Q8BWG8	—	1.000	Q8BWG8 →
Q4R562	—	0.995	Q4R562 →
Q95223	—	0.985	Q95223 →
P32121	—	0.971	P32121 →
Q5RCR4	—	0.969	Q5RCR4 →
P32120	—	0.955	P32120 →
Q13888	—	0.936	Q13888 →
Q6P1K8	—	0.931	Q6P1K8 →
Q5SP67	—	0.930	Q5SP67 →
Q2TBV5	—	0.930	Q2TBV5 →
Q9JIB4	—	0.929	Q9JIB4 →
A0JN27	—	0.927	A0JN27 →
Q5ZJQ7	—	0.925	Q5ZJQ7 →
Q4W5Z4	—	0.923	Q4W5Z4 →
Q17QI2	—	0.921	Q17QI2 →
Q8K2H6	—	0.920	Q8K2H6 →
SSU72	RNA polymerase II subunit A C-terminal domain phosphatase SSU72	0.920	landscape →
Q2YDH1	—	0.920	Q2YDH1 →
P63073	—	0.919	P63073 →
Q91854	—	0.919	Q91854 →
Q4KLK9	—	0.919	Q4KLK9 →
P63074	—	0.918	P63074 →
KCNT1	Potassium channel subfamily T member 1	0.918	landscape →
Q1RML1	—	0.918	Q1RML1 →
EIF4E	Eukaryotic translation initiation factor 4E	0.917	landscape →
Q8C6G8	—	0.917	Q8C6G8 →
Q7RTP6	—	0.917	Q7RTP6 →
Q9UM13	—	0.917	Q9UM13 →